# Immusoft Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immusoft

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.immusoft.com
- Total disclosed funding: $28M
- Latest round: Series B (Jan 3, 2019)
- Investors on record: 8

## About

Based in the US, Immusoft Corporation is a developer of innovative cell therapies, focusing on programming B cells to produce therapeutic proteins for patients with rare diseases.Immusoft Corporation specializes in innovative cell therapies that program B cells to produce therapeutic proteins. Founded in 2009 in Seattle, US by Matthew Scholz, the company has raised a total of USD 4.50 mn across 13 funding deals. The latest funding round, a Grant for USD 8.00 mn, was led by the California Institute for Regenerative Medicine.Immusoft specializes in innovative cell therapies that focus on programming B cells to produce therapeutic proteins, especially for patients suffering from rare diseases. Their core technology, Immune System Programming (ISP™), programs a patient's B cells to transform into plasma cells, which act as biofactories for therapeutic proteins. The flagship product, ISP-001, is advancing toward clinical studies to treat Mucopolysaccharidosis type I (MPS I), addressing specific therapy needs in the rare disease market, primarily serving patients, healthcare providers, and research institutions in North America and Europe.Immusoft generates revenue through partnerships and collaborations in the biotechnology sector, aimed at developing and commercializing proprietary cell therapy products. Their agreements with pharmaceutical companies and healthcare providers typically include milestone payments and royalties based on product sales, emphasizing long-term relationships that leverage their technological expertise in cell programming.Immusoft Corporation plans to utilize the recent funding from NYBC Venture to support the development and launch of new products. The company aims to expand its market presence in North America and Europe, with specific targets for new geographical regions by 2025. This strategy involves enhancing their flagship product ISP-001, which is crucial for their partnership-driven revenue model.

## Funding rounds

- Series B, Jan 3, 2019, $20M — Mesa Verde Venture Partners, Alexandria Venture Investments, DEFTA Partners, Breakout Ventures, RBV Capital
- Series B, Jan 5, 2018, $3M — RBV Capital, Technium Partners, 600 Mile Challenge Fund
- Series A, Nov 1, 2016, $2.7M — Founders Fund
- Series A, Aug 20, 2014, $2.4M — Founders Fund

## Investors

- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series A
- RBV Capital — Series B
- Technium Partners — Series B
- 600 Mile Challenge Fund (https://capitalatlas.ai/funds/600-mile-challenge-fund) — Series B
- Mesa Verde Venture Partners (https://capitalatlas.ai/funds/mesa-verde-venture-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Series B
- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Series B